查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772236

全球 Rozanolixizumab（Rystiggo）市場：市場規模、佔有率、趨勢分析（按適應症、分銷管道和地區）、細分市場預測（2025-2033）

Rozanolixizumab (Rystiggo) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Emerging Pipeline Applications), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Rozanolixizumab (Rystiggo) 市場摘要

2024 年全球 Rozanolixizumab (Rystiggo) 市場規模估計為 2.1861 億美元，預計到 2033 年將達到 17.004 億美元，2025 年至 2033 年的複合年成長率為 15.22%。慢性尋常性乾癬和銀屑病關節炎盛行率的不斷上升推動了對先進生物製藥的需求。

重症全身性肌無力 (gMG) 的核准推動了市場發展。國際趨勢包括標靶治療藥物需求的不斷成長以及全球監管部門的核准，這主要得益於核准可能性的提高和醫療資源的增加。優時比 (UCB) 的創新方法和新興產品線支撐了市場成長。羅扎諾利珠單抗 (Rystiggo) 市場針對的是 gMG，一種慢性自體免疫免疫疾病，其盛行率的上升正在推動需求成長。 Rystiggo 已在美國和歐洲核准，可皮下注射，並能有效降低 IgG 抗體，從而刺激了該藥物的推廣。市場成長的驅動力在於診斷率的上升以及人口老化，後者更容易患上自體免疫疾病。優時比致力於擴大其適應症，預計到 2033 年，適應症將進一步增加。

Rystiggo 的主要優勢在於其創新的 FcRn 標靶機制，可顯著改善吞嚥和呼吸等重症肌無力 (gMG) 症狀，已在 MycarinG 研究中得到證實。與血漿置換相比，Rystiggo 可在維持療效的同時減少副作用。皮下給藥提高了患者的便利性，使其在靜脈注射治療中佔據優勢。

新興創新包括慢性發炎去髓鞘化綜合症 (CIDP) 檢測和自我給藥。成功的產品線擴展預計將使潛在市場到 2033 年翻倍。給藥系統的進步旨在提高依從性，而生物相似藥的潛力可能帶來競爭，同時在長期內平衡成本和可近性。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. Rozanolixizumab（Rystiggo）市場：變數、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL分析
    • 管道分析
    • 專利到期分析
    • 定價分析

4. Rozanolixizumab（Rystiggo）市場：按適應症進行的商業分析

  • 各適應症市場佔有率（2024 年及 2033 年）
  • 細分儀表板：依指示
  • 市場規模預測及趨勢分析（2021-2033）
  • 全身性重症肌無力（gMG）
  • 其他

第5章 Rozanolixizumab（Rystiggo）市場：通路業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板：按分銷管道
  • 按分銷管道分類的市場規模預測和趨勢分析（2021-2033 年）
  • 醫院和專科藥房
  • 零售與電子商務

第6章 Rozanolixizumab（Rystiggo）市場：按地區估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2033 年）
  • 市場儀表板：按地區
  • 各地區市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 按國家/地區（2021-2033 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • UCB
Product Code: GVR-4-68040-644-4

Rozanolixizumab (Rystiggo) Market Summary

The global rozanolixizumab (Rystiggo) market size was estimated at USD 218.61 million in 2024 and is projected to reach USD 1,700.40 million by 2033, growing at a CAGR of 15.22% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

The market is driven by its approval for generalized myasthenia gravis (gMG). Key trends include rising demand for targeted therapies and global regulatory approvals, fueled by potential approvals and increasing healthcare access. Growth is supported by UCB's innovative approach and emerging pipeline applications. The rozanolixizumab (Rystiggo) market targets gMG, a chronic autoimmune disorder, with growing prevalence driving demand. Approved in the U.S. and Europe, Rystiggo's subcutaneous administration and efficacy in reducing IgG antibodies fuel its adoption. Market growth is propelled by rising diagnosis rates and an aging population susceptible to autoimmune diseases. UCB's focus on expanding indications further supports the projected increase by 2033.

Rystiggo's key advantage lies in its novel FcRn-targeting mechanism, offering significant improvements in gMG symptoms like swallowing and breathing, as demonstrated in the MycarinG study. Compared to plasma exchange, it reduces side effects while maintaining efficacy. Its subcutaneous delivery enhances patient convenience, positioning it favorably against intravenous competitors.

Emerging innovations include trials for chronic inflammatory demyelinating syndrome (CIDP) and self-administration methods. Successful pipeline expansion could double the addressable market by 2033. Advances in delivery systems aim to improve compliance, while potential biosimilars may introduce competition, balancing cost and accessibility in the long term.

Global Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rozanolixizumab (Rystiggo) market report based on indication, distribution channel and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Generalized Myasthenia Gravis (gMG)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital & Specialty Pharmacies
  • Retail & E Commerce
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Generalized Myasthenia Gravis (gMG)
    • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital & Specialty Pharmacies
    • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail & E-Commerce
    • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Rozanolixizumab (Rystiggo) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rozanolixizumab (Rystiggo) Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Rozanolixizumab (Rystiggo) market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rozanolixizumab (Rystiggo) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rozanolixizumab (Rystiggo) market dynamics
  • Fig. 12 Rozanolixizumab (Rystiggo) market: Porter's five forces analysis
  • Fig. 13 Rozanolixizumab (Rystiggo) market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
  • Fig. 16 Emerging Pipeline Applications market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital & Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail & E-Commerce market, 2021 - 2033 (USD Million)
  • Fig. 20 Rozanolixizumab (Rystiggo) market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 North America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 29 Europe Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 30 UK country dynamics
  • Fig. 31 UK Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 32 Germany country dynamics
  • Fig. 33 Germany Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 34 France country dynamics
  • Fig. 35 France Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 36 Italy country dynamics
  • Fig. 37 Italy Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 38 Spain country dynamics
  • Fig. 39 Spain Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway country dynamics
  • Fig. 41 Norway Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden country dynamics
  • Fig. 43 Sweden Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 44 Denmark country dynamics
  • Fig. 45 Denmark Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 46 Asia Pacific Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 47 Japan country dynamics
  • Fig. 48 Japan Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 49 China country dynamics
  • Fig. 50 China Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 51 India country dynamics
  • Fig. 52 India Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia country dynamics
  • Fig. 54 Australia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 55 South Korea country dynamics
  • Fig. 56 South Korea Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil country dynamics
  • Fig. 61 Brazil Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina country dynamics
  • Fig. 63 Argentina Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 64 MEA Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 65 South Africa country dynamics
  • Fig. 66 South Africa Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 67 Saudi Arabia country dynamics
  • Fig. 68 Saudi Arabia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 69 UAE country dynamics
  • Fig. 70 UAE Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 71 Kuwait country dynamics
  • Fig. 72 Kuwait Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 73 Company categorization
  • Fig. 74 Company market position analysis
  • Fig. 75 Strategic framework